Article

ASCRS 2023: Cenegermin 0.002%: effective for corneal nerve regeneration in neurotrophic keratitis

Author(s):

In a presentation at the American Society for Cataract and Refractive Surgery annual meeting in San Diego, Ana Balbuena-Pareja, MSc, explained how cenegermin-bkbj ophthalmic solution 0.002% (Oxervate, Dompé) had a positive effect on corneal nerve regeneration and sensation in patients with neurotrophic keratitis.

a close image of a microscope looking at a slide with dna on it. (Image Credit: AdobeStock/kkolosov)

For each evaluation, 3 representatives in vivo confocal microscopy images were selected and graded in a masked fashion for total, main, and branch nerve density. (Image Credit: AdobeStock/kkolosov)

According to research by a team from Tufts Medical Center in Boston, cenegermin-bkbj ophthalmic solution 0.002% (Oxervate, Dompé) had a positive effect on corneal nerve regeneration and sensation in patients with neurotrophic keratitis.

Ana Balbuena-Pareja, MSc, and the team of investigators reported their findings at the American Society of Cataract and Refractive Surgery annual meeting in San Diego.

The authors carried out a retrospective study of patients treated at the New England Eye Center for neurotrophic keratitis from January 1, 2015, to March 31, 2022. All eligible patients completed a minimum of 4 weeks of treatment with cenegermin 0.002% and had in vivo confocal microscopy images taken before and after treatment available.

For each evaluation, 3 representatives in vivo confocal microscopy images were selected and graded in a masked fashion for total, main, and branch nerve density.

The group comprised of 25 patients with neurotrophic keratitis (mean age, 64.2; 28.0% male) and the control group that included 20 patients (mean age, 58.4; 40%male) were similar in age and sex.

The results showed that the median total, main, and branch nerve densities were lower in the neurotrophic keratitis group before treatment, respectively, 2,301.0, 1,653.5, and 547.9 µm/mm² compared with the respective controls values, 22,253.7, 10,130.95, and 12,080.9 (p < 0.001 for all comparisons).

Following treatment with cenegermin, the densities increased to 5,306.7 for total (p = 0.004), main 3,452.0 (p = 0.005), and branch 1,987.9 (p = 0.019) nerve densities. Corneal sensation also increased after treatment from 2.3 cm to 4.1 cm (p = 0.001).

The authors concluded that the patients with neurotrophic keratitis who were treated for at least 4 weeks with cenegermin 0.002% had an overall increase in the total, main, and branch nerve densities. These results also demonstrated a significant increase in corneal sensation after cenegermin treatment.

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
Lisa Nijm, MD, says preoperative osmolarity testing can manage patient expectations and improve surgical results at the 2025 ASCRS annual meeting
At the 2025 ASCRS Annual Meeting, Weijie Violet Lin, MD, ABO, shares highlights from a 5-year review of cross-linking complications
Maanasa Indaram, MD, is the medical director of the pediatric ophthalmology and adult strabismus division at University of California San Francisco, and spoke about corneal crosslinking (CXL) at the 2025 ASCRS annual meeting
(Image credit: Ophthalmology Times) ASCRS 2025: Taylor Strange, DO, assesses early visual outcomes with femto-created arcuate incisions in premium IOL cases
(Image credit: Ophthalmology Times) ASCRS 2025: Neda Shamie, MD, shares her early clinical experience with the Unity VCS system
Patricia Buehler, MD, MPH, founder and CEO of Osheru, talks about the Ziplyft device for noninvasive blepharoplasty at the 2025 American Society of Cataract and Refractive Surgeons (ASCRS) annual meeting
(Image credit: Ophthalmology Times) ASCRS 2025: Bonnie An Henderson, MD, on leveraging artificial intelligence in cataract refractive surgery
(Image credit: Ophthalmology Times) ASCRS 2025: Gregory Moloney, FRANZO, FRCSC, on rotational stability
Sheng Lim, MD, FRCOphth, discusses the CONCEPT study, which compared standalone cataract surgery to cataract surgery with ECP, at the 2025 ASCRS Annual Meeting.
(Image credit: Ophthalmology Times) ASCRS 2025: Steven J. Dell, MD, reports 24-month outcomes for shape-changing IOL
© 2025 MJH Life Sciences

All rights reserved.